Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.2, Iss.3, 2003-05, pp. : 263-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cerebrovascular Profile Assessment in Parkinson’s Disease Patients

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 712-717

Bentham Science Publishers

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors in Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinsons Disease

By Kaakkola S.

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Parkinson’s Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors

Current Drug Metabolism, Vol. 17, Iss. 5, 2016-06 ,pp. : 513-518

Bentham Science Publishers

Access to resources Recommend Favorite

Catechol- O -Methyltransferase Inhibitors in Parkinson's Disease: Guidelines for Effective Use

By Davis T.L.

CNS Drugs, Vol. 10, Iss. 4, 1998-10 ,pp. : 239-246

Adis International

Access to resources Recommend Favorite